PMID- 29511875
OWN - NLM
STAT- MEDLINE
DCOM- 20190403
LR  - 20211204
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 20
IP  - 4
DP  - 2018 Mar 6
TI  - Evolocumab: Considerations for the Management of Hyperlipidemia.
PG  - 17
LID - 10.1007/s11883-018-0720-3 [doi]
AB  - PURPOSE OF REVIEW: To review the efficacy, safety, pharmacology, and 
      pharmacokinetics of evolocumab, a proprotein convertase subtilisin/kexin type 9 
      (PCSK9) inhibitor. RECENT FINDINGS: PCSK9 inhibitors are a class of 
      lipid-lowering agents that significantly reduce low-density lipoprotein 
      cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular 
      disease and hyperlipidemia. Evolocumab is a monoclonal antibody that inhibits 
      PCSK9 and has been evaluated in phase II and III studies as monotherapy, in 
      combination with statins and other lipid-lowering therapies, in patients who are 
      statin intolerant, and in patients with heterozygous and homozygous familial 
      hypercholesterolemia. Data from these studies show that evolocumab significantly 
      reduces LDL-C levels. Treatment with evolocumab also significantly improves 
      levels of other lipid parameters (e.g., apolipoproteins A1 and B, lipoprotein(a), 
      non-high-density lipoprotein cholesterol, and triglycerides). Recent results 
      indicate that LDL-C reduction with evolocumab significantly reduces the risk of 
      cardiovascular events and is also associated with atherosclerotic plaque 
      regression. From a safety standpoint, rates of adverse events (AEs), serious AEs, 
      and AEs leading to discontinuation were similar between evolocumab and controls 
      in clinical trials, and no increase in AEs was observed when evolocumab was used 
      in combination with statins. Patients with elevated LDL-C benefit from evolocumab 
      treatment, suggesting that evolocumab could help meet an unmet medical need in 
      high-risk patient populations with atherosclerotic cardiovascular disease and 
      hyperlipidemia that are unable to reduce LDL-C levels sufficiently with statin 
      therapy alone.
FAU - Wiggins, Barbara S
AU  - Wiggins BS
AD  - Department of Pharmaceutical Sciences, Pharmacy Clinical Specialist-Cardiology, 
      Medical University of South Carolina, Charleston, SC, USA. wiggib@musc.edu.
FAU - Senfield, Jeffrey
AU  - Senfield J
AD  - Clinical Cardiac Electrophysiologist, Novant Health Heart and Vascular Institute, 
      1718 East 4th Street, Suite 607, Charlotte, NC, 28204, US.
FAU - Kassahun, Helina
AU  - Kassahun H
AD  - Clinical Research Medical Director, Amgen Inc., Thousand Oaks, CA, USA.
FAU - Lira, Armando
AU  - Lira A
AD  - Clinical Research Medical Director, Amgen Inc., Thousand Oaks, CA, USA.
FAU - Somaratne, Ransi
AU  - Somaratne R
AD  - Global Development Executive Medical Director, Amgen Inc., Thousand Oaks, CA, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180306
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (PCSK9 Inhibitors)
RN  - EC 3.4.21.- (PCSK9 protein, human)
RN  - LKC0U3A8NJ (evolocumab)
SB  - IM
MH  - Antibodies, Monoclonal/pharmacokinetics/pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Anticholesteremic Agents/pharmacokinetics/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypercholesterolemia/*drug therapy
MH  - Hyperlipidemias/drug therapy
MH  - PCSK9 Inhibitors
MH  - Risk Factors
OTO - NOTNLM
OT  - Evolocumab
OT  - Low-density lipoprotein cholesterol
OT  - PCSK9
OT  - Statins
EDAT- 2018/03/08 06:00
MHDA- 2019/04/04 06:00
CRDT- 2018/03/08 06:00
PHST- 2018/03/08 06:00 [entrez]
PHST- 2018/03/08 06:00 [pubmed]
PHST- 2019/04/04 06:00 [medline]
AID - 10.1007/s11883-018-0720-3 [pii]
AID - 10.1007/s11883-018-0720-3 [doi]
PST - epublish
SO  - Curr Atheroscler Rep. 2018 Mar 6;20(4):17. doi: 10.1007/s11883-018-0720-3.